Associated Papers
Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies.
Jingnuo D et al.
Journal of Gastroenterology and Hepatology, 2026
Clinical relevance of mosaic variants detected by exome sequencing.
Ghosh R et al.
The Journal of Allergy and Clinical Immunology, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Management of Mastocytosis and Mast Cell Activation in Children.
Carter MC et al.
The Journal of Allergy and Clinical Immunology. in Practice, 2026
Germ cell immunoprofile and KIT exon 17 mutation guide rectification of seminoma misclassified as epithelioid gastrointestinal stromal tumor: A case report.
Zhang X et al.
Biomedical Reports, 2026
Genetic diversity in melanomagenesis: a comprehensive analysis of BRAF, NRAS, KIT and novel mutations across melanoma subtypes.
Göze ÖF et al.
Bmc Cancer, 2025
Well-differentiated systemic mastocytosis: Genetics, mast cell immunophenotypes, and KIT autophosphorylation.
Schornack BJ et al.
The Journal of Allergy and Clinical Immunology, 2025
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Voss RK et al.
Leukemia, 2025
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
Cheng WY et al.
Blood, 2025
KIT amplitude-based multiplex droplet digital polymerase chain reaction outperforms direct sequencing for sensitive KIT D816 genotyping in core binding factor acute myeloid leukemia.
Mizuta S et al.
Laboratory Medicine, 2025
Telomere occupancy by TRF2 is altered by KIT mutations and correlates with mastocytosis regression.
Bruneau J et al.
Blood Cancer Journal, 2025
Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution.
Hablesreiter R et al.
Experimental Hematology & Oncology, 2025
Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.
Umeda M et al.
Blood, 2025
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia.
Montalban-Bravo G et al.
Blood Advances, 2025
Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges.
Sotiropoulou CD et al.
European Journal of Haematology, 2025
Next Generation Sequencing of Genes With Epigenetic Alterations in Mastocytosis.
Górska A et al.
Clinical and Translational Allergy, 2025
Novel KIT mutation, D816_N819delinsll, in a patient with systemic mastocytosis: a case report.
Juratli HA et al.
Virchows Archiv : an International Journal of Pathology, 2025
A structurally informed human protein-protein interactome reveals proteome-wide perturbations caused by disease mutations.
Xiong D et al.
Nature Biotechnology, 2025
Myeloid sarcoma shows a high frequency of mutations activating the MAPK/ERK pathway and association with clonal hematopoiesis.
Nann D et al.
The Journal of Pathology. Clinical Research, 2025
Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type.
Yang X et al.
Human Genomics, 2025
Erythroblastic Sarcoma in Adults and Children: Different Pathways to the Same Destination.
Fitzpatrick MJ et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Mast Cell Leukemia: Comprehensive Review of Literature With Current Insights and Updates on Management.
Idamakanti M et al.
Journal of Hematology, 2025
Computational modeling of human genetic variants in mice.
Dong K et al.
Biorxiv : the Preprint Server for Biology, 2025
A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.
Wang Y et al.
Scientific Data, 2025
Clinical and Biological Characteristics of Four Patients with Aggressive Systemic Mastocytosis Treated with Midostaurin.
Soare D et al.
Biomedicines, 2025
M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer.
Esdar C et al.
Molecular Cancer Therapeutics, 2025
Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review.
Getz TM et al.
Annals of Hematology, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia.
Shu W et al.
European Journal of Medical Research, 2025
Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia.
Chow RD et al.
Blood Advances, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.
Umeda M et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Dasatinib maintenance following allogeneic transplantation in acute myeloid leukemia with KIT mutation.
Ngo D et al.
Bone Marrow Transplantation, 2025
Mast Cell Sarcoma of the Small Intestine Diagnosed by Ascitic Fluid Cytology: A Case Report with Molecular and Immunophenotypic Correlation.
Mizoguchi K et al.
Acta Cytologica, 2025
The importance of targeted next-generation sequencing based genomic profiling in the diagnosis of childhood acute myeloid leukemia: a single center experience.
Kaçar D et al.
The Turkish Journal of Pediatrics, 2024
Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML.
Wu Y et al.
Nature Communications, 2024
MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.
Cai X et al.
Bmc Cancer, 2024
Detection of KIT Mutations in Systemic Mastocytosis: How, When, and Why.
Cilloni D et al.
International Journal of Molecular Sciences, 2024
Early drivers of clonal hematopoiesis shape the evolutionary trajectories of de novo acute myeloid leukemia.
Chow RD et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.
Wang Q et al.
Annals of Hematology, 2024
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik A et al.
Journal of Hematology & Oncology, 2024
[Analysis of the therapeutic effect of avatinib bridged allogeneic hematopoietic stem cell transplantation on 7 cases of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia with KIT mutations].
Han SY et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2024
Prevalence and impact of the KIT M541L variant in patients with mastocytosis.
Aldama LND et al.
Oncotarget, 2024
Whole-exome sequencing has revealed novel genetic characteristics in intracranial germ cell tumours in the Chinese.
Huang X et al.
Histopathology, 2024